Use of drug-eluting balloon coronary intervention prior to living donor kidney transplantation

BMC Cardiovasc Disord. 2014 Sep 1:14:112. doi: 10.1186/1471-2261-14-112.

Abstract

Background: Kidney transplantation is the gold standard of therapy in patients with terminal renal insufficiency. Living donor transplantation is a well-established option in this field. Enlarging the donor's pool implicates the acceptance of an increased rate of comorbidities. Among them, coronary artery disease is a growing problem. An increasing number of patients, undergoing living donation, receive antiplatelet therapies due to coronary disease.

Case presentation: Here we report about the perioperative treatment with a drug-eluting balloon in a patient with major cardiac risk factors who underwent kidney transplantation.

Conclusion: At the current time no recommendation can be given for the routine use of drug-eluting balloons.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Angioplasty, Balloon, Coronary / adverse effects
  • Angioplasty, Balloon, Coronary / instrumentation*
  • Anticoagulants / administration & dosage
  • Coronary Angiography
  • Coronary Artery Disease / diagnosis
  • Coronary Artery Disease / therapy*
  • Coronary Restenosis / diagnosis
  • Coronary Restenosis / etiology
  • Coronary Restenosis / therapy*
  • Coronary Thrombosis / etiology
  • Coronary Thrombosis / therapy
  • Diabetic Nephropathies / diagnosis
  • Diabetic Nephropathies / surgery*
  • Drug-Eluting Stents*
  • Humans
  • Kidney Transplantation / methods*
  • Living Donors*
  • Male
  • Patient Care Team
  • Percutaneous Coronary Intervention / adverse effects
  • Percutaneous Coronary Intervention / instrumentation*
  • Platelet Aggregation Inhibitors / administration & dosage
  • Prosthesis Design
  • Risk Factors
  • Time Factors
  • Treatment Outcome

Substances

  • Anticoagulants
  • Platelet Aggregation Inhibitors